SciClone Pharmaceuticals Inc. (NASDAQ:SCLN)’s share price traded up 2.3% during mid-day trading on Thursday . The company traded as high as $10.97 and last traded at $10.53, with a volume of 424,423 shares changing hands. The stock had previously closed at $10.29.

The firm has a market capitalization of $517.56 million and a P/E ratio of 19.20. The stock’s 50-day moving average price is $13.39 and its 200-day moving average price is $11.22.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter. The business earned $36.50 million during the quarter, compared to analyst estimates of $33.60 million. On average, equities analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.

A number of institutional investors have added to or reduced their stakes in SCLN. Dimensional Fund Advisors LP boosted its position in SciClone Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,559,182 shares of the specialty pharmaceutical company’s stock worth $23,544,000 after buying an additional 53,987 shares during the last quarter. Matarin Capital Management LLC acquired a new position in SciClone Pharmaceuticals during the fourth quarter worth $1,600,000. Cornerstone Capital Management Holdings LLC. boosted its position in SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock worth $1,827,000 after buying an additional 48,470 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its position in SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock worth $2,991,000 after buying an additional 54,227 shares during the last quarter.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.